‏Comparison of the effect of adding nebulized low molecular weight heparin to the treatment of patients with Covid 19 who are treated with Remdesivir on an outpatient basis compared to the usual treatment during five days

Determination and clinical effectiveness of low molecular weight heparin on lung inflammation and acute respiratory syndrome was done.

Clinical trial with control group, double blind, randomized, phase 3 on 42 patients. SPSS version 25 was used for randomization.

The study is double-blind. The patients and the person analyzing the study results will not know about the treatment groups.Patients referred to Razi Ahvaz Hospital are divided into two equal groups and the peak expiratory flow rate is measured by Peak flowmeter, and the vital signs of the patients are also measured and recorded, then the appropriate dose of Remdesivir and the appropriate dose of low molecular weight heparin (0.5 mg per kilogram) are given to one of the groups and the other group will be given the appropriate dose of Remdesivir and nebulized distilled water for 5 days on an outpatient basis.

Inclusion criteria:‏patients with a diagnosis of covid-19, who have clinical and paraclinical criteria, and with symptoms of shortness of breath. Exclusion criteria: ‏Patients with poor general condition and hospitalization in the emergency room and ICU, heart disease, acute medical problems, pregnant women, patients with suspicion of Pulmonary thromboembolism , kidney problems, coagulation problems, and drug sensitivity.

The intervention group includes patients with Covid-19 who are subjected to the intervention of the appropriate dose of Remdesivir and the appropriate dose of low molecular weight heparin (0.5 mg per kilogram). The control group includes patients with Covid-19 who are treated with the appropriate dose of Remdesivir and nebulized distilled water.

Peak expiratory flow rate؛ respiratory rate; saturation O2

The participants are individually divided into two groups based on the 4-way random block permutation method and using SPSS version 25 software (version 25, IBM Corporation, Armonk, NY), which is allocation concealment by using sequentially numbered, opaque, sealed envelopes will be done in random order.

This study is a double-blind study. Participants will be divided into two groups of low molecular weight heparin nebulization and placebo nebulization, which is the same color and undetectable to the patient. In such a way that the person who administers the medicine in the two groups will be different from the person who examines the results of the interventions. The interventions are performed by the emergency nurse, but the peak flowmetry results are measured by an intern who is unaware of the intervention groups. Also, the patients and the person who analyzes the results of the study will not know about the treatment groups.